Testing clenbuterol for muscle health in FSHD
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This study tests a medication called clenbuterol to see if it can reduce activity of the DUX4 gene, which is believed to cause muscle damage in FSHD. If you have FSHD type 1 or 2, you may be able to join and help researchers understand if this drug can improve muscle health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a genetic test confirming FSHD type 1 or 2, or a first-degree relative with a confirmed mutation
- You are between 18 and 75 years old
- You can walk 30 feet without help from another person
- You are able to move your ankle upward against gravity (anti-gravity motion) in at least one leg, or have a leg muscle that appears suitable for a needle biopsy on an MRI
- You are not currently taking certain medications like beta-blockers, steroids, blood thinners, or GLP-1 drugs (Ozempic-like), and you are not pregnant or planning pregnancy during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how children with FSHD move and function over time. It uses walking tests and optional MRI scans to understand muscle changes. Your child's participation could help researchers learn more about FSHD progression in kids.
This study tests a new medicine called SRP-1001 to see if it can help people with a type of muscular dystrophy called FSHD1. It aims to slow down muscle weakness and improve quality of life.
This trial tests a new stem cell treatment (ULSC) for people with FSHD, a type of muscular dystrophy. It aims to see if the treatment is safe and if it can help improve arm strength and daily movement.
This study is testing a new medicine, SFL-0821, to see if it is safe and useful for people with FSHD. It may help if it works, but it is still experimental.
This study tests a new medicine called SAT-3247 to see if it can safely improve muscle strength in people with facioscapulohumeral muscular dystrophy (FSHD), a condition that causes muscle weakness, especially in the face, shoulders, and legs. Participating may help you and future patients by finding a treatment that could slow or reduce muscle loss.
This study tests whether a drug called apitegromab can help improve muscle function in people with facioscapulohumeral muscular dystrophy (FSHD). It is for adults aged 18-60 who have mild to moderate symptoms and can walk or run 10 meters in 5 seconds or less.
Hear when a new Muscular Dystrophy, Facioscapulohumeral trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.